• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

SHYFT Analytics Lands $12.5M Backed by McKesson Ventures, Medidata

by Jasmine Pennic 09/02/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

SHYFT Analytics

SHYFT Analytics, a provider of cloud data and analytics for the global life sciences industry has raised $12.5 million in Series B funding. SHYFT Management opted for an all strategic collaboration, which included investments from McKesson Ventures, Medidata Solutions and other healthcare and technology industry leaders. SHYFT will use the investment to continue its rapid growth and expansion and further advance its leading healthcare cloud analytics platform. Existing investors, Health Enterprise Partners and Milestone Venture Partners, also participated in the round.

Life sciences companies are facing an increasingly complex healthcare environment, which is fundamentally changing the way products are developed and commercialized. Founded in 2010, SHYFT’s cloud platform SHYFT’s Clinical Analytics service integrates all aspects of new product planning (clinical, commercial, competitive, market access) into one common platform leveraging the most reliable data sources to inform cross-functional collaboration and decision-making. 

SHYFT customers develop treatments across broad and emerging therapeutic areas with a strong focus on oncology, cardiovascular disease, diabetes, and other specialty and rare disorders.

With the recent launch of SHYFT RWE, a first of its kind solution that aggregates EMR data and delivers real world treatment outcomes and analytics, SHYFT is now able to optimize observational research at scale. In a single application, SHYFT customers can now conduct end-to-end patient and disease studies in days rather than months for research focused on drug safety, comparative effectiveness, drug utilization, treatment pathways and patient outcomes.

Current clients already include two of the top 10 global pharmaceutical companies and a rapidly expanding customer base in Specialty, Rare Disease, and Biotechnology. 

“Life Sciences companies are rapidly adopting analytics to increase their commercial efficiency and to improve the clinical effectiveness of their drugs,” said Dave Schulte, managing director of McKesson Ventures in a statement. “SHYFT’s cloud-based platform provides the necessary foundation for superior enterprise data management, integration and visualization. Their impressive growth and strong customer demand positions SHYFT as the market leader, particularly in the category of analyzing real world outcomes for pharmaceutical treatments.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Healthcare Data Analytics, McKesson Ventures, Medidata, SHYFT Analytics

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |